Valeant’s Bausch and Lomb: To Sell Or Not To Sell?

As the world watches and waits for Valeant Pharmaceuticals Intl Inc VRX 2.04%‘s next move, activist investor and new Valeant board member Bill Ackman says the move will not involve the sale of Bausch & Lomb. Ackman cleared up the Bausch & Lomb issue in an interview with CNBC following reports by FOX Business Network’s…